INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 1993

Grapefruit juice and naringenin inhibit CYP1A2-dependent caffeine metabolism in humans.

Researchers evaluated the effects of grapefruit juice and naringenin on human CYP1A2 activity using caffeine as a probe substrate. In vitro, naringin competitively inhibited caffeine 3-demethylation by human liver microsomes (Ki = 7-29 microM). In vivo among 12 participants, grapefruit juice (1.2 l day-1 containing 0.5 g l-1 naringin) decreased oral caffeine clearance by 23% (95% CI: 7%-30%) and prolonged its half-life by 31% (95% CI: 20%-44%). The authors concluded that while grapefruit juice inhibits CYP1A2, the small in vivo effect suggests it generally should not cause clinically significant inhibition of other CYP1A2 drug substrates.

Study type
Intervention trial with in vitro microsomal component
Who was studied
12 human participants (in vivo) and human liver microsomes (in vitro)
What was measured
Caffeine oral clearance, half-life, and in vitro caffeine 3-demethylation inhibition

THE PAPER

Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

Fuhr U, Klittich K, Staib AH. Br J Clin Pharmacol, 1993.

PubMed 8485024 ↗DOI 10.1111/j.1365-2125.1993.tb04162.x ↗

Food safety & contaminantsOther healthTop 21: Oranges & citrus

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.